Purpose of review: The development of a preventive HIV vaccine remains an unresolved challenge. Animal models that can predict the results of HIV vaccine efficacy trials and identify the immune mechanisms responsible for vaccine protection would be most useful for HIV vaccine development. The purpose of the current review is to critique recent developments in the use of animal models of HIV infection in preclinical studies of AIDS vaccines and to describe how the use of improved animal models can inform the development of an HIV vaccine.
Recent findings: The results of preclinical experiments with candidate HIV vaccines can vary with the SIV challenge virus used. It is now known that there is considerable variability in the neutralization sensitivity and that the level of viral sequence diversity within the challenge stocks varies. This has allowed more realistic preclinical vaccine studies with heterologous vaccine antigens and challenge viruses. Further, the dose of challenge virus and the route of virus challenge can modify the efficacy of candidate vaccines in preclinical studies.
Summary: Recent experiments demonstrate that nonhuman primate models of AIDS can reproduce the complex biology of HIV transmission, recapitulate the results of HIV vaccine efficacy trials in humans and be used to identify correlates of protection.
aCalifornia National Primate Research Center
bCenter for Comparative Medicine, University of California, Davis, California, USA
Correspondence to Christopher J. Miller, CNPRC, UC Davis, One Shields Ave, Davis, CA 95616, USA. Tel: +1 530 752 0447; fax: +1 530 752 2880; e-mail: email@example.com
The development of a preventive HIV vaccine remains an unresolved challenge . This effort began in 1985 after the isolation and characterization of the virus and there have been clinical efficacy trials of three candidate HIV vaccines; Vaxgen's gp120, Merck's Ad5-HIV gag/pol/nef and the RV144 trial of a vaccine consisting of priming with Sanofi's ALVAC-HIV gag/pol/env and boosting with Vaxgen's gp120 . The results of these efficacy trials were disappointing. The Vaxgen vaccine provided no protection from HIV acquisition in high-risk people. In homosexual men, the Merck Ad5-based vaccine provided no benefit and may have enhanced HIV acquisition in a subset of recipients participating in the Step trial. Finally, the initial analysis of the results of the RV144 trial of the ALVAC prime/ gp120 boost vaccine concluded that the vaccine provided modest protection from HIV acquisition in low-risk heterosexuals  and a virologic analysis suggested that specific HIV-1 variants were blocked from establishing HIV-1 infection or that viral sequences evolved as part of a postinfection sieve effect . However, a more recent statistical analysis of the RV144 trial data concluded that vaccination had low-level efficacy, ‘with more than or equal to 22% chance remaining for no efficacy under a range of previous assumptions’ ; thus, there is greater uncertainty about the results of this trial than is generally acknowledged.
Recently, another HIV vaccine trial, HVTN 505, was halted because of lack of efficacy (http://http://www.niaid.nih.gov/news/newsreleases/2013/Pages/HVTN505April2013.aspx). The vaccine consisted of three immunizations with DNA that encoded gag, pol, nef from clade B HIV-1 and env from HIV clades A, B and C followed by boosting with a recombinant Ad5 vector that contained gag/pol from HIV clade B and env from HIV clades A, B and C. Despite the exclusion of risk factors from the earlier STEP trial (see discussion below), the inclusion of envelope immunogens and the use DNA priming, the vaccine was not effective at preventing HIV acquisition or reducing viral load postinfection. In fact, as with the STEP trial, more HIV infections (n = 41) occurred in the vaccinees than in placebo vaccine recipients (n = 30). These 4 clinical trials consumed vast amounts of human and financial resources and may not have provided a commensurate level of insight into the means to produce an effective HIV vaccine , as the type, quality and magnitude of the immune responses that correlate with protection against HIV infection in humans cannot be determined until a vaccine demonstrates robust protection in a clinical trial.
Although the current approach to HIV-1 vaccine testing assumes that vaccine immunogenicity is a surrogate measure of vaccine efficacy, the validity of this assumption is unknown . In fact, many HIV-1 vaccine candidates that are immunogenic in mice and nonhuman primates (NHP) have elicited only weak and/or transient immune responses in humans . Because immunogenicity in NHP has been a poor predictor of human immune responses, it is generally accepted that a rigorous preclinical approach to judging the potential efficacy of an HIV vaccine candidate is to determine whether it can protect the NHP from the uncontrolled replication of a virulent challenge virus that recapitulates the pathogenic effects of HIV-1 in humans . Although the vaccine candidates discussed above were tested for efficacy against simian immunodeficiency virus (SIV) or simian–human immunodeficiency virus (SHIV) viral challenges in NHP models, the approaches employed did not alert the field to the potential weaknesses of these candidate vaccines. The purpose of the current review is to critique recent developments in the use of animal models of HIV infection and to describe how the improved use of animal models can inform the development of an HIV vaccine. There are two primary uses of animal models in the current exploratory phase of HIV vaccine development: testing candidate vaccine effectiveness (ability to prevent viral infection or blunt viral replication) and identifying immune correlates of protection that can be followed in subsequent clinical trials to determine whether they are also correlates of protection from HIV acquisition or infection in humans.
HIV is transmitted primarily by sexual contact, and the genital tract and rectum are the major anatomic sites of virus transmission . Thus, it may be important for candidate HIV vaccines to elicit immune responses in these mucosal tissues. Preclinical studies to test the ability of an HIV vaccine to prevent mucosal virus transmission are becoming more common (reviewed in ), as SIV and SHIV can be experimentally transmitted to rhesus macaques by rectal, vaginal and penile inoculation resulting in systemic infection with a single or a few SIV env variants [7–10]. NHP models have been critical for understanding how AIDS viruses enter these mucosal tissues, infect target cells and disseminate from mucosal surfaces [11,12]. After mucosal inoculation, HIV and SIV rapidly penetrate the mucus covering the epithelial surface and infect intraepithelial dendritic cells and CD4+ T cells in the epithelium and lamina propria . These infected cells enter draining lymphatics and can be found in the proximal lymph nodes 18–24 h after virus exposure . However, there is a little detectable viral replication in tissues until 5–7 days after infection, when there are simultaneous and dramatic increases in viral replication and innate immune responses in all tissues [11,14]. It was reported that plasmacytoid dendritic cells (pDC) accumulate in the reproductive tract mucosa soon after vaginal SIV exposure , leading to the conclusion that the viral inoculum initiates an ‘outside-in’ signaling pathway that recruits pDC and T cells to the cervix and this putative influx of target cells supports the expansion of the nascent viral infection in the new host . This interpretation of early events has recently been called into question, as the number of pDC in the endocervix of normal rhesus macaques is highly variable and pDC can be found below and within the columnar epithelium of the cervix of monkeys never exposed to virus [17▪].
As with sexual HIV transmission [7,16,18–21], SIV or SHIV infections are established by a very limited number (1 or 2) of viral env variants after mucosal inoculation [8,9,22]. This is a critical feature for preclinical vaccine testing; vaccine-induced immune responses may only need to prevent infection or replication of a small number of genetically homogenous virions transmitted during an exposure to HIV. Finally, intravenous inoculation of rhesus macaques with plasma from SIV-infected animals demonstrated that acute-phase plasma virions are more infectious than chronic-phase virions . Similarly, it was recently reported that transmitted/founder HIV virions are more infectious in vitro than chronic-phase viruses [24▪]. These recent insights and advances demonstrate that the virology of mucosal transmission in NHP faithfully models the biology of HIV sexual transmission.
The strengths and weaknesses of NHP and human/mouse chimeric models used for AIDS research have been recently reviewed [25▪] and will not be discussed in detail here. As most HIV vaccine testing has been done in NHP models, this will be the focus of review. Cellular antiviral restriction factors in Asian macaques can block replication of some SIV strains, a situation that requires that SIV challenge strains be matched with the NHP species used [25▪].
It is important to note that the results of SIV vaccine experiments can vary with the SIV challenge virus used. Thus, a DNA/Ad5 vaccine that afforded partial protection against acquisition of SIVsmE660 afforded no protection against SIVmac251 . A large number of monkeys were vaccinated with a plasmid DNA prime/recombinant adenovirus serotype 5 (rAd5) boost vaccine regimen and then they were challenged intrarectally with either SIVmac251 or SIVsmE660 every week for 12 weeks. The vaccine had no impact on acquisition of the neutralization-resistant SIVmac251, but provided a 50% reduction in infection with the neutralization-sensitive SIVsmE660. Low levels of neutralizing antibodies and a CD4+ T-cell response against Env correlated with the protection. Critically, however, protection against SIVsmE660 only occurred in monkeys that had two TRIM5 alleles that restrict SIV replication in host cells, whereas monkeys expressing one TRIM5 allele that is permissive for SIV replication were not protected . As restricting TRIM5 alleles have no effect on SIVmac251 acquisition or replication in NHP vaccine studies  and restricting TRIM5 alleles can block acquisition of SIVsmE660 in unvaccinated animals , the simplest interpretation of the above study is that this vaccine regimen was protective only in a host expressing restricting TRIM5 alleles and challenged with a virus that is susceptible to TRIM5 restriction. Although there are viral strain-specific differences in the sensitivity of HIV-1 to human TRIM5-α alleles in vitro, there is no evidence that TRIM5-α alleles reduce susceptibility to HIV infection or decrease virus replication in humans. Thus, NHP experiments with an SIV vaccine that was equivalent to the HIV vaccine tested in HVTN 505 accurately predicted the lack of protection in that trial.
The SIV stocks used in NHP experiments are generated by transfection of viral genomes and/or by in-vitro expansion of virus isolates in T cells and the details of virus production may affect in-vivo infectivity, mucosal transmissibility and early infection events. A recent analysis of nine SIV challenge virus stocks demonstrated that all stocks had similar particle-to-infectivity ratios, but the level of viral sequence diversity within the infection-derived SIVmac251 stocks varied, with evidence of selection and expansion of unique viral lineages in different 251 stocks [29▪]. Although an HIV vaccine must protect against highly divergent virus strains [30▪,31], most preclinical vaccine studies in NHP models have used challenge viruses that match the immunogens in the vaccine. This is not a realistic approach to assessing the potential for vaccine efficacy against a highly variable pathogen, and more recent studies have used vaccine antigens and challenge viruses that are mismatched in the envelope gene sequence by up to 20% [32,33▪▪]. Although these heterologous challenge models are more realistic, future studies that incorporate a pool of viruses with a range of sensitivity to antibody neutralization or that contain CTL escape mutant epitopes into a virus challenge may yield even more information regarding the potential of a vaccine to be effective against antigenically divergent HIV strains.
ROUTE AND DOSE OF VIRUS CHALLENGE
Vaccine-induced immune responses that correlate with protection from virus infection may be broadly distributed and capable of providing protection from many routes of challenge, or they may be narrowly focused on a specific site of transmission [17▪]. Further, the extent to which a mucosal surface serves as a barrier to transmission varies by anatomic site. Thus, rectal SIV transmission is more efficient than vaginal transmission, which is more efficient than penile transmission .
Accurately modeling the different mucosal routes of HIV exposure that will occur among human trial participants in preclinical NHP testing of a candidate vaccine is likely to be necessary to predict the potential effectiveness of the vaccine in people. The Phase IIb STEP trial of the Ad5 HIV-1 subtype B vaccine was halted because of futility [34,35] and it was subsequently found that there were an increased number of HIV-1 infections in Ad5-seropositive male vaccine recipients with an intact foreskin . In preclinical NHP experiments, the Ad5 vector-based vaccines were highly effective against intravenous challenge with SHIV89.6P [36–38]. The inability of SHIV challenge to predict the results of the STEP trial led to the conclusion that NHP models using SHIV are not adequate for preclinical evaluation of candidate HIV vaccines . Indeed, subsequent NHP studies showed that Ad5-SIV vaccines are ineffective at preventing infection after intrarectal SIV challenge , and that an Ad5-SIV vaccine enhanced SIV transmission after low-dose penile virus challenge . The above results demonstrate that NHP models using challenge viruses that recapitulate HIV pathogenesis and routes of exposure that mimic the complexity of HIV sexual transmission can reflect the results of a human vaccine trial.
In an NHP study designed to model the RV144 trial, NHP were immunized with a prime of ALVAC-SIV and boosted with gp120 in a vaccine regimen similar to the RV144 trial. After the immunized animals were challenged intrarectally with a low dose of SIV, three of the 11 vaccinated macaques were protected from SIV infection, but this rate of transmission was not significantly different than in the unimmunized control animals [41▪] and was much less than the 60% level of protection seen in the RV144 trial early after the final immunization . The inability to achieve similar levels of protection in humans and NHP with the RV144 vaccine may be because of the fact that the clinical trial enrolled low-risk heterosexual humans that were presumably not exposed to HIV rectally, whereas the NHP were challenged intrarectally with SIV. Thus, the route of challenge in NHP studies should mirror the route of HIV transmission that is most important within the human population that is participating in the clinical trial.
In addition to route of challenge, it is clear that the results of preclinical NHP vaccine studies are also affected by the dose of challenge virus used. A recent vaccine study found that immunized NHP challenged rectally with a single high dose of SIV were not protected from infection, whereas three of 12 animals challenged twice with a 10-fold lower virus dose were protected [42▪]. In another NHP study, an Ad5-SIV vaccine enhanced SIVmac239 transmission after repeated penile low-dose SIV challenge, but had no effect on SIV acquisition upon challenge with higher SIV doses . Thus, the dose of challenge virus can greatly influence vaccine efficacy in preclinical NHP studies. Using a repeated challenge model with escalation of the virus challenge dose from subinfectious to high dose over the course of 21 weeks , the potential for vaccine-enhanced transmission at a subinfectious viral challenge dose and the limits of vaccine-induced protection in the face of higher doses were revealed.
NHP studies of HIV-1 vaccine candidates have begun to elucidate immunologic correlates of protection against neutralization-sensitive viruses [26,43] and homologous, neutralization-resistant viruses [17▪], but only recently has an SIV vaccine mediated protection against acquisition of heterologous, neutralization-resistant virus challenge [33▪▪], allowing immunologic correlates to be tested in a setting that more realistically models HIV infection. Ultimately, animal models that can predict the results of HIV vaccine efficacy trials and identify the immune mechanisms responsible for vaccine protection would be most useful for HIV vaccine development. NHP models of HIV transmission have proved their value as the results of a large NHP study  predicted the lack of efficacy in the HVTN 505 trial, as the candidate vaccine provided no protection against rectal challenge with SIVmac251. Further, another recent relative large NHP study demonstrated that Ad5 vector vaccine-elicited SIV-specific immune responses, but not Ad5 specific immunity, were associated with an increased risk of HIV acquisition after penile inoculation with very low doses of SIVmac251 [29▪]. Thus, the combined results of the NHP STEP study and the HVTN505 trial demonstrate that Ad5 specific immunity did not alter HIV susceptibility in vaccinees, and strongly suggest that HIV-specific T-cell responses elicited by vaccination enhanced HIV acquisition in the STEP and HVTN505 trials.
Although preclinical animal models may not be appropriate as a gatekeeper for entry of candidate HIV vaccines into human trials, they can and should be used to understand how a candidate vaccine actually work to either enhance or decrease HIV transmission, so that clinical trials can be designed to measure the immune responses that matter [44▪]. The recent developments reviewed above demonstrate that NHP models of AIDS can reproduce the complex biology of HIV transmission and that these models can recapitulate the results of HIV vaccine efficacy trials in humans.
Conflicts of interest
The authors are supported by NIH Grant P51RR00169 to the California National Primate Research Center, University of California-Davis and R01 s R01AI10271 and AI066314 (to CJM) from the National Institute of Allergy and Infectious Disease.
The authors declare no conflicts of interest.
REFERENCES AND RECOMMENDED READING
Papers of particular interest, published within the annual period of review, have been highlighted as:
▪ of special interest
▪▪ of outstanding interest
Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 511–512).
1. Kim JH, Rerks-Ngarm S, Excler JL, et al. HIV vaccines: lessons learned and the way forward. Curr Opin HIV AIDS 2010; 5:428–434.
2. Rolland M, Edlefsen PT, Larsen BB, et al. Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 2012; 490:417–420.
3. Gilbert PB, Berger JO, Stablein D, et al. Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials. J Infect Dis 2011; 203:969–975.
4. Morgan C, Marthas M, Miller C, et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med 2008; 5:e173.
5. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol 2008; 8:447–457.
6. Genesca M, Miller CJ. Use of nonhuman primate models to develop mucosal AIDS vaccines. Curr HIV/AIDS Rep 2010; 7:19–27.
7. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A 2008; 105:7552–7557.
8. Keele BF, Li H, Learn GH, et al. Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med 2009; 206:1117–1134.
9. Stone M, Keele BF, Ma ZM, et al. A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol 2010; 84:7083–7095.
10. Ma ZM, Keele BF, Qureshi H, et al. SIVmac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a single SIVenv variant found in ramp-up phase plasma. AIDS Res Hum Retroviruses 2011; 27:1259–1269.
11. Miller CJ, Li Q, Abel K, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol 2005; 79:9217–9227.
12. Stone M, Ma ZM, Genescà M, et al. Limited dissemination of pathogenic SIV after vaginal challenge of rhesus monkeys immunized with a live, attenuated lentivirus. Virology 2009; 392:260–270.
13. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000; 74:6087–6095.
14. Abel K, Rocke DM, Chohan B, et al. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol 2005; 79:12164–12172.
15. Li Q, Skinner PJ, Ha SJ, et al. Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science 2009; 323:1726–1729.
16. Abrahams MR, Anderson JA, Giorgi EE, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 2009; 83:3556–3567.
17▪. Genesca M, Ma ZM, Wang Y, et al. Live-attenuated lentivirus immunization modulates innate immunity and inflammation while protecting rhesus macaques from vaginal simian immunodeficiency virus challenge. J Virol 2012; 86:9188–9200.
Protective immunity against vaginal SIV challenge is associated with local control of inflammation and local expansion of CD4+ regulatory T cells.
18. Haaland RE, Hawkins PA, Salazar-Gonzalez J, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009; 5:e1000274.
19. Kearney M, Maldarelli F, Shao W, et al. Human immunodeficiency virus type 1 population genetics and adaptation in newly infected individuals. J Virol 2009; 83:2715–2727.
20. Salazar-Gonzalez JF, Bailes E, Pham KT, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008; 82:3952–3970.
21. Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009; 206:1273–1289.
22. Liu J, Keele BF, Li H, et al. Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol 2010; 84:10406–10412.
23. Ma ZM, Stone M, Piatak M Jr, et al. High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol 2009; 83:3288–3297.
24▪. Parrish NF, Gao F, Li H, et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A 2013; 110:6626–6633.
HIV-1 isolates from acute or chronic infection subjects were compared using several virologic and biologic parameters. Acute infection isolates were more infectious and had higher density of envelope protein.
25▪. Hatziioannou T, Evans DT. Animal models for HIV/AIDS research. Nat Rev Microbiol 2012; 10:852–867.
This excellent review of animal models for HIV research discusses the provenance of commonly used SIV challenge virus stocks and the potential for creating molecular mixtures for virus challenge experiments.
26. Letvin NL, Rao SS, Montefiori DC, et al. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci Transl Med 2011; 3:81ra36.
27. Fenizia C, Keele BF, Nichols D, et al. TRIM5alpha does not affect simian immunodeficiency virus SIV(mac251) replication in vaccinated or unvaccinated Indian rhesus macaques following intrarectal challenge exposure. J Virol 2011; 85:12399–12409.
28. Battivelli E, Lecossier D, Matsuoka S, et al. Strain-specific differences in the impact of human TRIM5alpha, different TRIM5alpha alleles, and the inhibition of capsid-cyclophilin A interactions on the infectivity of HIV-1. J Virol 2010; 84:11010–11019.
29▪. Del Prete GQ, Scarlotta M, Newman L, et al. Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies. J Virol 2013; 87:4584–4595.
Nine commonly used SIV challenge virus stocks were compared systematically using several virologic and biologic properties. Surprisingly, transfection-derived SIVmac239 stocks were more infectious in vitro, but had much lower envelope protein density.
30▪. Hemelaar J. Implications of HIV diversity for the HIV-1 pandemic. J Infect 2013; 66:391–400.
This recent review of the circulating clades and recombinant strains of HIV-1 of the M group that make up the global pandemic discusses how both geographic and intrahost genetic diversity contribute to the challenge of making a prophylactic vaccine.
31. Gaschen B, Taylor J, Yusim K, et al. Diversity considerations in HIV-1 vaccine selection. Science 2002; 296:2354–2360.
32. Reynolds MR, Weiler AM, Weisgrau KL, et al. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 2008; 205:2537–2550.
33▪▪. Barouch DH, Liu J, Li H, et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 2012; 482:89–93.
This well designed experiment allows exploration of immune correlates of protection from repeated, low-dose rectal SIV challenge.
34. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881–1893.
35. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894–1905.
36. Shiver JW, Fu TM, Chen L, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002; 415:331–335.
37. Letvin NL, Huang Y, Chakrabarti BK, et al. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 2004; 78:7490–7497.
38. Liang X, Casimiro DR, Schleif WA, et al. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol 2005; 79:12321–12331.
39. Casimiro DR, Cox K, Tang A, et al. Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challenge. J Virol 2010; 84:2996–3003.
40. Qureshi H, Ma ZM, Huang Y, et al. Low dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus 5 then immunized with a replication defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the Phase IIb Step trial of a similar HIV-1 vaccine. J Virol 2011; 86:2239–2250.
41▪. Pegu P, Vaccari M, Gordon S, et al. Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol 2013; 87:1708–1719.
This SIV/macaque experiment closely modelled the ALVAC prime and gp120 boost vaccine trial, demonstrating similar vaccine immunogenicity as seen in humans, but there was no significant protection from SIV acquisition following repeated, low-dose rectal SIV challenge.
42▪. Vaccari M, Keele BF, Bosinger SE, et al. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J Virol 2013; 87:3538–3548.
This is the only SIV vaccine experiment, to our knowledge, that compared directly the dose of challenge virus, in this case inoculated rectally. Repeated, low-dose mucosal exposure in SIV vaccine experiments probably models the sexual transmission of HIV-1 better than a single, high-dose exposure that is sufficient to infect all of the control animals. And this article suggests that vaccine-induced adaptive immunity could protect against the low-dose challenge better.
43. Barnett SW, Burke B, Sun Y, et al. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 2010; 84:5975–5985.
44▪. Shapiro SZ. HIV vaccine development: strategies for preclinical and clinical investigation. AIDS Res Hum Retroviruses 2013; 29: Epub ahead of print doi 10.1089/AID.2012.0337.
This is an excellent discussion of the strategies that will allow continued development of HIV vaccines in light of reduced resources and the high cost of clinical trials. The FDA's new ’animal rule’ is discussed in relation to the use of animal models for testing HIV vaccines.